Follow
Farasat Bokhari
Farasat Bokhari
Verified email at uea.ac.uk
Title
Cited by
Cited by
Year
Government health expenditures and health outcomes
FAS Bokhari, Y Gai, P Gottret
Health economics 16 (3), 257-273, 2007
4312007
School accountability laws and the consumption of psychostimulants
FAS Bokhari, H Schneider
Journal of Health Economics 30 (2), 355-372, 2011
692011
An analysis of the significant variation in psychostimulant use across the US
F Bokhari, R Mayes, RM Scheffler
Pharmacoepidemiology and Drug Safety 14 (4), 267-275, 2005
632005
Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity
GT Ray, P Levine, LA Croen, FAS Bokhari, T Hu, LA Habel
Archives of pediatrics & adolescent medicine 160 (10), 1063-1069, 2006
612006
OPEN VERSUS CLOSED FIRMS AND THE DYNAMICS OF INDUSTRY EVOLUTION*
A Arora, FAS Bokhari
The Journal of Industrial Economics 55 (3), 499-527, 2007
58*2007
Entry in the ADHD drugs market: Welfare impact of generics and me‐too's
FAS Bokhari, GM Fournier
The Journal of industrial economics 61 (2), 339-392, 2013
57*2013
Managed care competition and the adoption of hospital technology: The case of cardiac catheterization
FAS Bokhari
International Journal of Industrial Organization 27 (2), 223-237, 2009
40*2009
Risk factors for discontinuing drug therapy among children with ADHD
FAS Bokhari, F Heiland, P Levine, GT Ray
Health Services and Outcomes Research Methodology 8, 134-158, 2008
182008
WHO.(2000)
S Anand, M Ravaillion, P Berman, F Bokhari, Y Gai, P Gottret, D Cutler, ...
World Health Report: Health Systems Improving Performance. Geneva: World …, 0
17
Demand estimation and merger simulations for drugs: Logits v. AIDS
FAS Bokhari, F Mariuzzo
International Journal of Industrial Organization 61, 653-685, 2018
142018
Assessing the impact of health care expenditures on mortality using cross-country data
R Nakamura, J Lomas, K Claxton, F Bokhari, R Moreno-Serra, M Suhrcke
Global Health Economics-Shaping Healthcare Policy in Low-and Middle-Income …, 2020
132020
What is the price of pay-to-delay deals?
FAS Bokhari
Journal of Competition Law and Economics 9 (3), 739-753, 2013
132013
Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals
FAS Bokhari, F Mariuzzo, A Polanski
Journal of Economics & Management Strategy 29 (3), 516-542, 2020
11*2020
Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions
FAS Bokhari, F Mariuzzo, AR Bennato
Small Business Economics 57 (1), 603-634, 2021
52021
Selective admission into stroke unit and patient outcomes: a tale of four cities
FAS Bokhari, I Wellwood, AG Rudd, P Langhorne, MS Dennis, CDA Wolfe
Health economics review 4, 1-10, 2014
52014
Rise of ADHD prevalence and psychostimulant use: A historical perspective
R Mayes, F Bokhari
130th Annual Meeting of APHA, Abstract 46109, 2002
42002
Antibacterial resistance and the cost of affecting demand: The case of uk antibiotics
F Bokhari, F Mariuzzo, W Yan
mimeo, 2018
32018
Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market
FAS Bokhari, W Yan
Available at SSRN 3675109, 2020
22020
Competition issues in the distribution of pharmaceuticals [website]
S Vogler
Paris: OECD, 2014
22014
Banning volume discounts to curb excessive consumption: A cautionary tale
FAS Bokhari, PW Dobson, M Morciano, M Suhrcke
European Economic Review 156, 104480, 2023
12023
The system can't perform the operation now. Try again later.
Articles 1–20